Key Takeaways
- Among 554,316 Ontario adults with a new solid tumour cancer, 0.3% had a non-fatal opioid overdose and 0.03% a fatal one.
- High-dose opioids (50 mg or more morphine-equivalent a day) were linked to about 3.5 times the overdose rate, rising 3% per month on high-dose therapy.
- Stage IV cancer carried 6.24 times the first-year overdose rate of stage I.
Cancer Pain Needs Treatment. But How Much Opioid Is Too Much?
A cancer diagnosis can bring pain that makes ordinary life difficult. For many patients, opioid medications are an essential part of getting through treatment.
But doctors face a difficult balance: relieve the pain without exposing patients to unnecessary overdose risk.
A major Ontario study has put numbers behind that challenge.
Researchers followed 554,316 adults newly diagnosed with solid tumour cancers between 2013 and 2020. Their findings, published November 10, 2026, in JAMA Network Open, show that opioid overdose was uncommon.
But the risk was far from equal across patients.
How Rare Was an Overdose?
Among the 554,316 patients:
1,591 people (0.3%) experienced at least one non-fatal opioid overdose.
191 people (0.03%) experienced a fatal opioid overdose.
Some patients could appear in both figures if they experienced a non-fatal overdose before a fatal one.
The researchers used linked Ontario health records from ICES and followed patients until their first overdose, death or December 31, 2024.
The overall numbers were small. But looking only at those totals would hide an important finding.
Certain patients faced substantially higher overdose rates.
Advanced Cancer Was Linked to Higher Risk
The first year after a cancer diagnosis was particularly important.
Compared with patients diagnosed with stage I cancer, those with stage III cancer had 2.55 times the overdose hazard during that first year.
For stage IV cancer, the figure climbed to 6.24 times.
Stage IV generally means the cancer has spread to distant parts of the body.
These figures describe relative hazards, not the percentage of patients who overdosed. They also do not prove that advanced cancer itself caused the higher risk.
Still, the difference was substantial.
Higher Opioid Doses Carried a Stronger Warning
The researchers also examined opioid prescriptions.
Having an outpatient opioid prescription in the previous 30 days was associated with a 71% higher combined rate of fatal and non-fatal overdose, after statistical adjustment.
For patients prescribed high-dose opioids, the association was much stronger.
A daily dose equivalent to 50 milligrams or more of morphine was linked to approximately 3.5 times the overdose hazard.
Morphine equivalents allow researchers to compare the strength of different opioid medications using a common measure.
And dose was not the only factor.
Each additional month of high-dose opioid prescribing was associated with a 3% higher overdose hazard.
That does not mean every patient taking high-dose opioids experiences a predictable monthly increase in risk. It is an association observed across the study population.
The Risk Wasn't Limited to Patients With Opioid Use Disorder
One finding deserves particular attention.
Even among cancer patients without a recorded opioid use disorder, recent opioid prescriptions were associated with higher overdose rates.
In that group, any recent opioid prescription was linked to 1.80 times the overdose hazard.
High-dose prescribing was associated with 3.76 times the hazard.
The finding reinforces why overdose-risk assessment matters across cancer care, not only for patients with a documented history of opioid use disorder.
Honest Limits
This was an observational study, not a randomized clinical trial.
Researchers examined health records and prescribing patterns. They did not randomly assign patients to different opioid doses.
That means the findings show associations, not proof that the prescriptions caused the overdoses.
Patients receiving higher doses may also have had more severe pain, more advanced disease or other health challenges.
Cancer-stage information was also missing for a substantial portion of patients, limiting how broadly the stage comparisons can be interpreted.
And the findings describe patients diagnosed between 2013 and 2020, with follow-up ending in 2024. They should not be treated as a direct measure of Ontario's overdose situation today.
What This Means for Cancer Pain Treatment
The researchers are not suggesting that cancer patients should avoid opioids.
These medications remain important for managing moderate to severe cancer-related pain and other symptoms.
Instead, the findings support a more careful approach: prescribe the lowest effective dose, monitor patients closely and routinely assess overdose risk.
That matters especially when higher doses or longer treatment periods are being considered.
For patients, the message is not to stop prescribed medication because of a frightening statistic. Any concerns about dose, side effects or overdose risk should be discussed with the treating cancer-care team.
The Twikup Take
A medication can be essential and still carry risks that deserve attention.
This Ontario study found that opioid overdose after a cancer diagnosis was uncommon, but the relative hazard was considerably higher with advanced cancer and high-dose prescribing.
The goal is not less pain relief at any cost. It is effective pain relief with appropriate safeguards.
Cancer pain deserves treatment. Every opioid prescription deserves careful monitoring.
Image: Illustrative image.